FORM FOR ADVANCE VOTING

The shareholder stated below hereby cast his/hers/its votes in accordance with the instructions in <u>Schedule</u> <u>1</u> at the annual general meeting in Alligator Bioscience AB, Reg. No. 556597-8201, on 5 May 2020.

Shareholder

Name of the shareholder: Number of shares in Alligator Bioscience AB:		Personal identification number or corporate registration number: Daytime telephone number:		

If issued by a legal entity, the form must be signed by authorized representative(s) and be accompanied by a registration certificate or, concerning foreign legal entities, corresponding documents evidencing the authorized representative(s) of the shareholder.

The form, and a copy of the registration certificate or corresponding documents (if applicable) shall be sent to Alligator Bioscience AB, att Lotten Almén, Medicon Village, SE-223 81 Lund, Sweden, or via e-mail to <u>anmalan@alligatorbioscience.com</u>. The completed form must be submitted to Alligator Bioscience AB no later than Tuesday 28 April 2020.

In Schedule 1, the votes shall be set forth. A shareholder cannot give any other instructions than selecting one of the options specified at each point in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented. Only one form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The latest form received by the company will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered. For complete proposals for resolutions, please refer to the notice of the annual general meeting, the complete proposals and in respect of item 11 on the agenda "Determination of remuneration for the board members and the auditors", the Nomination Committee's updated proposal from 20 April 2020 on revised board remuneration, available at <u>www.alligatorbioscience.com</u>.

Should you have any questions, please contact Lotten Almén via e-mail to <u>anmalan@alligatorbioscience.com</u> or by phone to +46 (0)46-540 82 00.

Please note that submitting this form will be regarded as giving notice of your attendance at the annual general meeting. A prerequisite for an advance vote to be taken into account is that the shareholder who has cast the vote is included in the share register on the record date for the annual general meeting. Shareholders with nominee-registered shares must temporarily reregister their shares in their own name with Euroclear Sweden AB. Accordingly, shareholders must inform their trustee of this well in advance before Tuesday 28 April 2020.

This form for advance voting may be revoked by written notice to Alligator Bioscience AB on the address stated above or via e-mail to <u>anmalan@alligatorbioscience.com</u>, no later than Tuesday 28 April 2020. Thereafter, an advance vote can only be withdrawn if the shareholder is present, in person or by proxy, at the annual general meeting.

Schedule 1 to the Form for Advance Voting

Shareholder

_

Name of the shareholder:	Personal identification number or corporate registration number:
--------------------------	--

The votes below are cast by the shareholder above, for the resolutions at the annual general meeting in Alligator Bioscience AB, Reg. No. 556597-8201, on 5 May 2020, according to the proposed resolutions in the notice of the annual general meeting and in respect of item 11 on the agenda "Determination of remuneration for the board members and the auditors", the Nomination Committee's updated proposal from 20 April 2020 on revised board remuneration.

2. Ele	ction of Chairman of the meeting					
		Yes 🗆	No 🗆			
5. Ap	proval of the agenda					
		Yes 🗆	No 🗆			
6. Det	termination as to whether the meeting has been duly convened					
		Yes 🗆	No 🗆			
9. Res	solution on					
a)	adoption on the profit and loss statement and balance sheet, as well as the consolidated profit and loss statement and the consolidated balance sheet;	Yes 🗆	No 🗆			
	consolidated balance sheet,					
b)	distribution of the company's profits according to the adopted balance sheet; and	Yes 🗆	No 🗆			
c)	c) discharge from liability of the members of the board and the CEO					
	Per Norlén	Yes 🗆	No 🗆			
	Peter Benson	Yes 🗆	No 🗆			
	Carl Borrebaeck	Yes 🗆	No 🗆			
	Ulrika Danielsson	Yes 🗆	No 🗆			
	Graham Dixon	Yes 🗆	No 🗆			
	Kirsten Drejer	Yes 🗆	No 🗆			
	Anders Ekblom	Yes 🗆	No 🗆			
	Kenth Petersson	Yes 🗆	No 🗆			
	Jonas Sjögren	Yes 🗆	No 🗆			
	Laura von Schantz	Yes 🗆	No 🗆			
10. D	etermination of the number of board members as well as auditors a	and deputy	y auditors			
		Yes 🗆	No 🗆			
11. Determination of remuneration for the board members and the auditors						
		Yes 🗆	No 🗆			
12. El	ection of board members and Chairman of the board, auditor and d	eputy aud	litors			
Re-ele	ection of Peter Benson	Yes 🗆	No 🗆			
Re-ele	ection of Carl Borrebaeck	Yes 🗆	No 🗆			
Re-ele	ection of Ulrika Danielsson	Yes 🗆	No 🗆			
Re-ele	ection of Graham Dixon	Yes 🗆	No 🗆			
Re-ele	ection of Kirsten Drejer	Yes 🗆	No 🗆			
Re-ele	ection of Anders Ekblom	Yes 🗆	No 🗆			
Re-ele	ection of Kenth Petersson	Yes 🗆	No 🗆			
Re-ele	ection of Jonas Sjögren	Yes 🗆	No 🗆			
Re-ele	ection of Peter Benson as Chairman of the board	Yes 🗆	No 🗆			
Re-ele	ection of Ernst & Young AB	Yes 🗆	No 🗆			

_

13. Resolution on guidelines for remuneration to senior executives				
	Yes 🗆	No 🗆		
14. Resolution on authorization regarding issues				
	Yes 🗆	No 🗆		
15. Resolution on amendment of the Articles of Association				
	Yes 🗆	No 🗆		